{
    "clinical_study": {
        "@rank": "149889", 
        "brief_summary": {
            "textblock": "To compare the durability of the viral load response following 48 weeks of treatment with\n      1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone. To compare the early\n      antiviral activity following 16 weeks treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone as\n      demonstrated by the proportion of subjects with viral load < 400 copies/ml, plasma HIV-1 RNA\n      profiles and CD4+ profiles. To assess the safety and tolerance following 16 and 48 weeks of\n      treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone."
        }, 
        "brief_title": "The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study compares the safety and efficacy of 1592U89 in combination with 3TC and ZDV\n      versus control therapy with 3TC and ZDV alone. If a patient has two consecutive HIV-1 RNA\n      measurements of >= 400 copies/ml (performed at least one week apart) he or she has the\n      option to switch to open-label therapy with 1592U89/3TC/ZDV, to receive the remaining\n      randomized treatment, or to discontinue study medication. If this criterion is not met,\n      patients continue their randomly assigned therapy until the last patient has completed 48\n      weeks of therapy. Once patients enter the open-label phase, investigators may add or\n      substitute non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase\n      inhibitors, or protease inhibitors for 3TC and/or ZDV according to their standard practice\n      once patients enter the open-label phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Local treatment for Kaposi's sarcoma.\n\n          -  Hematologic supportive therapy with GM-CSF, G-CSF, or erythropoietin.\n\n        Patients must have:\n\n          -  HIV-1 infection as documented by a licensed HIV-1 antibody ELISA and confirmed by\n             either Western blot detection of HIV-1 antibody or positive HIV-1 blood culture.\n\n          -  One screening CD4 lymphocyte cell count >= 100 cells/mm3 within 14 days prior to\n             study drug administration.\n\n          -  No active or ongoing AIDS-defining opportunistic infection or disease.\n\n          -  Signed, informed consent from parent or legal guardian for patients under 18 years of\n             age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions and symptoms are excluded:\n\n          -  Malabsorption syndrome or other gastrointestinal dysfunction that might interfere\n             with drug absorption or render the patient unable to take oral medication.\n\n          -  Serious medical conditions such as diabetes, congestive heart failure,\n             cardiomyopathy, or other cardiac dysfunction, that, in the opinion of the\n             investigator, would compromise the safety of the patient.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Foscarnet therapy.\n\n          -  Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide,\n             anti-cytokine agents, or interferons.\n\n          -  Cytotoxic chemotherapeutic agents and antioxidants.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n        History of clinically relevant pancreatitis or hepatitis within the last 6 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior antiretroviral therapy.\n\n          -  Vaccination within the past 3 months given as part of an investigational HIV vaccine\n             trial.\n\n          -  Chemotherapeutic agents within 30 days of study drug administration.\n\n          -  Immunomodulating agents such as systemic corticosteroids, interleukins or\n             interferons, within 30 days of study drug administration.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Radiation therapy within 30 days of study period. Current alcohol or illicit drug use\n        that, in the opinion of the investigator, may interfere with the patient's ability to\n        comply with the dosing schedule and protocol evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "210", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002389", 
            "org_study_id": "238D"
        }, 
        "intervention": [
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Abacavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Antiviral Agents", 
            "Zidovudine", 
            "CD4 Lymphocyte Count", 
            "Lamivudine", 
            "RNA, Viral", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berkeley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94705"
                    }, 
                    "name": "East Bay AIDS Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Kraus Med Partners"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ of Miami Dept of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Med College / Rush Presbyterian - St Luke's Med Cen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "021182393"
                    }, 
                    "name": "Boston Med Ctr / Evans - 556"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07102"
                    }, 
                    "name": "Saint Michael's Med Ctr / Dept of Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10027"
                    }, 
                    "name": "Harlem Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "St Vincent's Hosp and Med Ctr / AIDS Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Univ Med Ctr / Dept of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "452670405"
                    }, 
                    "name": "Univ of Cincinnati / Holmes Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75225"
                    }, 
                    "name": "Dr Nicholaos Bellos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "770303498"
                    }, 
                    "name": "Baylor College of Medicine / Dept of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Toronto Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santurce", 
                        "country": "Puerto Rico", 
                        "zip": "00907"
                    }, 
                    "name": "San Juan AIDS Program"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts >= 100 Cells/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002389"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Baylor College of Medicine / Dept of Medicine": "29.76 -95.369", 
        "Boston Med Ctr / Evans - 556": "42.358 -71.06", 
        "Dr Nicholaos Bellos": "32.803 -96.77", 
        "Duke Univ Med Ctr / Dept of Medicine": "35.994 -78.899", 
        "East Bay AIDS Ctr": "37.872 -122.273", 
        "Georgetown Univ Med Ctr": "38.895 -77.036", 
        "Harlem Hosp": "40.714 -74.006", 
        "Kraus Med Partners": "34.052 -118.244", 
        "Rush Med College / Rush Presbyterian - St Luke's Med Cen": "41.878 -87.63", 
        "Saint Michael's Med Ctr / Dept of Infectious Diseases": "40.736 -74.172", 
        "San Juan AIDS Program": "18.441 -66.047", 
        "St Vincent's Hosp and Med Ctr / AIDS Ctr": "40.714 -74.006", 
        "Toronto Gen Hosp": "43.653 -79.383", 
        "Univ of Cincinnati / Holmes Hosp": "39.103 -84.512", 
        "Univ of Miami Dept of Medicine": "25.789 -80.226"
    }
}